ABBOTT LABORATORIES Acquisitions, Net of Cash Acquired
ABBOTT LABORATORIES (ABT) reported Acquisitions, Net of Cash Acquired of $160.00 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-07-31.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2019-07-31
- ABBOTT LABORATORIES payments to acquire businesses, net of cash acquired for the quarter ending 2019-06-30 was $82.00M, a 355.56% increase year-over-year.
- ABBOTT LABORATORIES payments to acquire businesses, net of cash acquired for the quarter ending 2019-03-31 was $78.00M, a 212.00% increase year-over-year.
- ABBOTT LABORATORIES payments to acquire businesses, net of cash acquired for the quarter ending 2018-06-30 was $18.00M.
- ABBOTT LABORATORIES payments to acquire businesses, net of cash acquired for the quarter ending 2018-03-31 was $25.00M, a 99.81% decline year-over-year.
- ABBOTT LABORATORIES payments to acquire businesses, net of cash acquired for fiscal 2017 was $17.18B, a 21378.75% increase from fiscal 2016.
- ABBOTT LABORATORIES payments to acquire businesses, net of cash acquired for fiscal 2016 was $80.00M, a 65.96% decline from fiscal 2015.
- ABBOTT LABORATORIES payments to acquire businesses, net of cash acquired for fiscal 2015 was $235.00M, a 92.92% decline from fiscal 2014.
- ABBOTT LABORATORIES payments to acquire businesses, net of cash acquired for fiscal 2014 was $3.32B, a 471.90% increase from fiscal 2013.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 3 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month as first filed | Payments to Acquire Businesses, Net of Cash Acquired 12 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-06-30 | $82.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $160.00M 10-Q · filed 2019-07-31 | ||||||
| 2019-03-31 | $78.00M 10-Q · filed 2019-05-01 | |||||||
| 2018-06-30 | $18.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $43.00M 10-Q · filed 2019-07-31 | $4.20B derived: sum of 3 quarters · filed 2019-07-31 | $4.20B derived: sum of 4 quarters · filed 2019-07-31 | ||||
| 2018-03-31 | $25.00M 10-Q · filed 2019-05-01 | $4.18B derived: sum of 2 quarters · filed 2019-05-01 | $4.18B derived: sum of 3 quarters · filed 2019-05-01 | $4.18B derived: sum of 4 quarters · filed 2019-05-01 | ||||
| 2017-12-31 | $4.16B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $4.16B derived: sum of 2 quarters · filed 2019-02-22 | $4.16B derived: sum of 3 quarters · filed 2019-02-22 | $17.18B 10-K · filed 2019-02-22 | ||||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $0.00 derived: sum of 2 quarters · filed 2018-10-31 | $13.03B 10-Q · filed 2018-10-31 | $13.03B derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $13.03B 10-Q · filed 2018-08-01 | $13.03B derived: sum of 3 quarters · filed 2019-02-22 | $13.10B derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-03-31 | $13.03B 10-Q · filed 2018-05-02 | $13.03B derived: sum of 2 quarters · filed 2019-02-22 | $13.10B derived: sum of 3 quarters · filed 2019-02-22 | |||||
| 2016-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $73.00M derived: sum of 2 quarters · filed 2019-02-22 | $80.00M 10-K · filed 2019-02-22 | |||||
| 2016-09-30 | $66.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $73.00M 10-Q · filed 2017-11-02 | ||||||
| 2016-06-30 | $7.00M 10-Q · filed 2017-08-02 | |||||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $231.00M derived: sum of 2 quarters · filed 2018-02-16 | $235.00M 10-K · filed 2018-02-16 | |||||
| 2015-09-30 | $231.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $235.00M 10-Q · filed 2016-11-03 | ||||||
| 2015-06-30 | $4.00M 10-Q · filed 2016-08-03 | |||||||
| 2014-12-31 | $495.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $3.32B 10-K · filed 2017-02-17 | ||||||
| 2014-09-30 | $2.82B 10-Q · filed 2015-11-05 | |||||||
| 2013-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $580.00M 10-K · filed 2016-02-19 | ||||||
| 2013-09-30 | $566.00M 10-Q · filed 2014-11-06 | $566.27M 10-Q · filed 2013-11-07 | ||||||
| 2012-12-31 | $24.38M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $46.00M derived: sum of 2 quarters · filed 2015-02-27 | $156.00M derived: sum of 3 quarters · filed 2015-02-27 | $706.00M 10-K · filed 2015-02-27 | $1.23B 10-K · filed 2013-02-15 | |||
| 2012-09-30 | $21.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $131.62M derived: sum of 2 quarters · filed 2013-11-07 | $681.62M 10-Q · filed 2013-11-07 | $1.20B 10-Q · filed 2012-11-07 | $282.12M derived: sum of 4 quarters · filed 2014-02-21 | |||
| 2012-06-30 | $110.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $660.00M 10-Q · filed 2013-08-06 | $780.85M 10-Q · filed 2012-08-07 | $260.50M derived: sum of 3 quarters · filed 2014-02-21 | $745.50M derived: sum of 4 quarters · filed 2014-02-21 | |||
| 2012-03-31 | $550.00M 10-Q · filed 2013-05-08 | $670.85M 10-Q · filed 2012-05-08 | $150.50M derived: sum of 2 quarters · filed 2014-02-21 | $635.50M derived: sum of 3 quarters · filed 2014-02-21 | ||||
| 2011-12-31 | -$399.50M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-21 | $85.50M derived: sum of 2 quarters · filed 2014-02-21 | $273.00M 10-K · filed 2014-02-21 | $672.50M 10-K · filed 2012-02-21 | ||||
| 2011-09-30 | $485.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $672.50M 10-Q · filed 2012-11-07 | ||||||
| 2011-06-30 | $187.50M 10-Q · filed 2012-08-07 | |||||||
| 2010-12-31 | $313.20M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $2.51B derived: sum of 2 quarters · filed 2013-02-15 | $3.02B derived: sum of 3 quarters · filed 2013-02-15 | $9.43B 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $2.20B derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $2.70B derived: sum of 2 quarters · filed 2011-11-04 | $9.12B 10-Q · filed 2011-11-04 | $9.97B derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $504.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-04 | $6.92B 10-Q · filed 2011-08-04 | $7.77B derived: sum of 3 quarters · filed 2012-02-21 | $7.78B derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | $6.42B 10-Q · filed 2011-05-06 | $7.27B derived: sum of 2 quarters · filed 2012-02-21 | $7.28B derived: sum of 3 quarters · filed 2012-02-21 | $7.29B derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2009-12-31 | $851.73M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $861.24M derived: sum of 2 quarters · filed 2012-02-21 | $878.57M derived: sum of 3 quarters · filed 2012-02-21 | $2.37B 10-K · filed 2012-02-21 | ||||
| 2009-09-30 | $9.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-05 | $26.84M derived: sum of 2 quarters · filed 2010-11-05 | $1.52B 10-Q · filed 2010-11-05 | $1.52B derived: sum of 4 quarters · filed 2011-02-18 | ||||
| 2009-06-30 | $17.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-05 | $1.51B 10-Q · filed 2010-08-05 | $1.51B derived: sum of 3 quarters · filed 2011-02-18 | |||||
| 2009-03-31 | $1.49B 10-Q · filed 2010-05-04 | $1.49B derived: sum of 2 quarters · filed 2011-02-18 | ||||||
| 2008-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $250.00M 10-K · filed 2011-02-18 | ||||||
| 2008-09-30 | $250.00M 10-Q · filed 2009-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |